FDA, Supernus and Parkinson's Disease

Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand name Onapgo—for use in adults with Parkinson’s disease.
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.
FDA approves Onapgo for motor fluctuations in adults with Parkinson’s disease
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus Pharmaceuticals Inc.
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s
Supernus stock surges on FDA approval
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
Supernus stock climbs 5% on FDA approval of Onapgo
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients with Parkinson's disease.
FiercePharma1d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
The Pharma Letter1h
FDA nod at last for Supernus’ Parkinson’s infusion therapy
It’s fourth time lucky for Supernus Pharmaceuticals (Nasdaq: SUPN), as the Parkinson’s specialist finally receives US ...
PMLiVE11h
FDA approves Supernus’ Onapgo to treat advanced Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Supernus Pharmaceuticals exec sells shares worth $376,236
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company that InvestingPro data shows maintains ...
Supernus announces FDA approval of ONAPGO
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as ...
New Atlas16h
US approves "milestone" Parkinson's treatment for 2025 release
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Supernus stock price target raised to $44 at TD Cowen
Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...